Peptide Stack for Fat Loss and Muscle Gain: CJC-1295, Ipamorelin, and AOD-9604

Body recomposition — simultaneously losing fat and gaining muscle — is notoriously difficult to achieve through diet and training alone. Optimizing growth hormone (GH) output is one of the most well-supported physiological levers for achieving recomposition, and a targeted peptide stack can meaningfully move that lever.

The combination of CJC-1295, ipamorelin, and AOD-9604 represents the current standard for evidence-informed peptide-based body recomposition protocols. Each compound contributes a distinct mechanism, and together they create additive rather than redundant effects.

Understanding the Three Compounds

CJC-1295 is a growth hormone releasing hormone (GHRH) analogue. It binds to GHRH receptors in the pituitary and stimulates the synthesis and release of GH. The DAC (Drug Affinity Complex) version of CJC-1295 has a half-life of approximately 8 days due to albumin binding, making it a long-acting compound that maintains elevated GH levels between injections. The non-DAC version (also called Modified GRF 1-29) has a much shorter half-life and is typically dosed more frequently — often combined with ipamorelin for a synergistic pulse.

Ipamorelin is a GH secretagogue that works through a different receptor (the ghrelin receptor) to release GH in pulses. When combined with CJC-1295, the two compounds work synergistically: CJC-1295 primes the pituitary and elevates baseline GH synthesis, while ipamorelin triggers a strong GH pulse at the time of injection. Clinical research has confirmed this synergistic effect produces significantly more GH release than either compound alone.

AOD-9604 is a modified fragment of human growth hormone (hGH176-191). It was developed specifically for fat metabolism and does not bind to the IGF-1 receptor, meaning it produces fat-burning effects without the muscle growth, insulin resistance, or IGF-1 elevation associated with full-length GH. Studies have demonstrated that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) without affecting blood glucose or insulin sensitivity. This makes it a precise fat-loss tool that complements GH-driven muscle-building without adding metabolic risk.

The Protocol: Dosing and Timing

CJC-1295 (with DAC)

• Dose: 1–2 mg once or twice per week
• Route: Subcutaneous injection
• Timing: Any time of day; the long half-life makes precise timing less critical
• Cycle: 8–12 weeks on, 4–6 weeks off

CJC-1295 (without DAC, Modified GRF 1-29) — alternative to DAC version

• Dose: 100 mcg per injection
• Frequency: 2–3x daily, combined in the same syringe as ipamorelin
• Timing: Morning fasted, pre-workout (fasted), and before bed

Ipamorelin

• Dose: 200–300 mcg per injection
• Frequency: 2–3x daily, combined with Modified GRF 1-29 if using non-DAC CJC
• Timing: Align with CJC-1295 injections
• Note: Always inject on an empty stomach (2+ hours post-meal, 30 min pre-meal)

AOD-9604

• Dose: 300 mcg once daily
• Route: Subcutaneous injection, ideally near the target fat area (though systemic distribution still occurs)
• Timing: Morning, fasted — this is when lipolysis is naturally most active
• Cycle: 12–16 weeks on, 4–6 weeks off; AOD-9604 has a favorable safety profile for longer runs

Timing Strategy for Maximum Recomposition

The relationship between insulin and GH is antagonistic — elevated insulin significantly blunts GH release. This makes meal timing around injections critical for this stack.

A practical daily schedule for maximum effect:

• 6:30 AM — AOD-9604 injection (fasted, on waking)
• 7:00 AM — CJC-1295/ipamorelin injection (combined in same syringe if using non-DAC)
• 7:30 AM — Fasted cardio or strength training (optional but enhances fat oxidation)
• 8:00–8:30 AM — First meal (high protein, moderate carbohydrate)
• 12:00–1:00 PM — Second CJC-1295/ipamorelin injection (optional, enhances overall GH output)
• 9:00–10:00 PM — Final CJC-1295/ipamorelin injection before bed (most important pulse)

If using CJC-1295 with DAC, the twice-weekly injection replaces the multiple non-DAC injections and significantly simplifies the protocol.

Diet Considerations for This Stack

Peptide stacks enhance your physiology's capacity for recomposition — they do not override a poor diet. The following nutritional approach maximizes the benefits of this stack:

Protein: 0.8–1.0 grams per pound of body weight daily. GH and IGF-1 drive protein synthesis, and adequate dietary protein is required for this to translate into muscle retention and growth. Prioritize complete protein sources: eggs, meat, fish, dairy, or complete plant combinations.

Carbohydrate timing: Concentrate carbohydrates around training and avoid them in the 2-hour window before injections. This keeps insulin low during injection windows and maximizes GH pulse amplitude.

Caloric approach: A modest caloric deficit of 300–500 calories below maintenance supports fat loss while the GH-driven environment protects lean mass. Aggressive restriction blunts GH response and is counterproductive. For pure muscle gain with minimal fat concern, a slight surplus of 200–300 calories with high protein works well.

Fat intake: Dietary fat does not blunt GH release the way carbohydrates and protein do. A moderate fat intake (0.4–0.5 g/lb) supports hormone production including testosterone, which works synergistically with GH for recomposition.

What Results to Expect

Weeks 1–3: Improved sleep, reduced water retention, slightly better recovery between sessions. Body composition changes are not yet visible.

Weeks 4–6: Measurable fat loss begins, particularly in stubborn areas (abdomen, lower back for men; hips and thighs for women). Strength and endurance improve noticeably. Muscle fullness increases.

Weeks 8–12: The most significant body composition shifts occur in this window. Users typically report 5–10 lbs of fat loss with 2–4 lbs of lean mass gained across a full 12-week cycle, though individual results vary considerably based on training, diet, and starting body composition.

Track IGF-1 levels at week 0 and week 6 to confirm biological activity. A doubling or more of IGF-1 from baseline suggests the GH-releasing peptides are working effectively. For a complete guide to reading your bloodwork, see tracking bloodwork for supplements.

Safety and Monitoring

This stack is generally well tolerated. The most common side effects include mild water retention in the first 2–3 weeks (from elevated GH), tingling in the hands or feet (also GH-related, typically transient), and occasionally mild lethargy after injections. These effects diminish as the body adapts.

AOD-9604 has completed Phase 2 clinical trials for obesity and has a clean safety record. It does not affect blood glucose or IGF-1. CJC-1295 and ipamorelin are well studied in their combined use. See our peptide stacking rules and safety guide for a comprehensive overview of monitoring recommendations.

Frequently Asked Questions

Q: Should I use CJC-1295 with or without DAC? Both versions work. CJC-1295 with DAC is more convenient (fewer injections) and maintains more stable GH levels. Non-DAC combined with ipamorelin produces stronger GH pulses but requires multiple daily injections. Beginners often prefer the DAC version for simplicity; more experienced users sometimes prefer the pulse pattern of non-DAC for training-aligned GH spikes.

Q: Can I add other fat-loss peptides to this stack? The most commonly added compound is MOTS-c for metabolic support, or tesamorelin for visceral fat specifically. However, adding compounds introduces complexity. For most people, CJC-1295 + ipamorelin + AOD-9604 is already a comprehensive fat-loss and recomposition stack and does not need additions.

Q: How important is fasted cardio with this stack? It is not mandatory, but fasted cardio in the morning — after AOD-9604 and the first CJC/ipamorelin injection — creates an environment of elevated lipolysis plus active fat utilization. The combination is synergistic. Even 20–30 minutes of moderate-intensity cardio in this window meaningfully accelerates fat loss results.

Q: Will this stack suppress my natural hormone production? Neither CJC-1295, ipamorelin, nor AOD-9604 suppresses endogenous GH production or the hypothalamic-pituitary axis. They work by stimulating natural GH release through physiological pathways, not by replacing GH. Pulsatile dosing and cycling off preserve long-term pituitary responsiveness.

Q: How does this stack compare to the beginner stack? The beginner stack uses ipamorelin alone without CJC-1295, and focuses more on tissue repair with BPC-157. This fat loss and muscle stack is more targeted for body recomposition and requires a slightly higher commitment to injection timing protocols. It is appropriate for someone who has completed at least one beginner peptide cycle.